Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness
Status:
Completed
Trial end date:
2018-02-28
Target enrollment:
Participant gender:
Summary
This open-label extension study will evaluate the long-term safety of glatiramer acetate and
its effect on the neurologic course of participants with relapsing-remitting multiple
sclerosis (RRMS). Participants have scheduled visits every 3 months to assess glatiramer
acetate safety and their Multiple Sclerosis (MS) status.
Phase:
Phase 4
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Branded Pharmaceutical Products, R&D Inc.